FR16C0042I2 - Derives de composes heterocycliques et medicaments - Google Patents
Derives de composes heterocycliques et medicamentsInfo
- Publication number
- FR16C0042I2 FR16C0042I2 FR16C0042C FR16C0042C FR16C0042I2 FR 16C0042 I2 FR16C0042 I2 FR 16C0042I2 FR 16C0042 C FR16C0042 C FR 16C0042C FR 16C0042 C FR16C0042 C FR 16C0042C FR 16C0042 I2 FR16C0042 I2 FR 16C0042I2
- Authority
- FR
- France
- Prior art keywords
- drugs
- derivatives
- heterocyclic compounds
- heterocyclic
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/18—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001129765 | 2001-04-26 | ||
PCT/JP2002/004118 WO2002088084A1 (fr) | 2001-04-26 | 2002-04-25 | Derives de composes heterocycliques et medicaments |
Publications (2)
Publication Number | Publication Date |
---|---|
FR16C0042I1 FR16C0042I1 (fr) | 2016-12-09 |
FR16C0042I2 true FR16C0042I2 (fr) | 2017-03-17 |
Family
ID=18978246
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR16C0042C Active FR16C0042I2 (fr) | 2001-04-26 | 2016-10-24 | Derives de composes heterocycliques et medicaments |
Country Status (19)
Country | Link |
---|---|
US (1) | US7205302B2 (fr) |
EP (1) | EP1400518B1 (fr) |
JP (1) | JP4479152B2 (fr) |
KR (1) | KR100921760B1 (fr) |
CN (1) | CN1301973C (fr) |
BE (1) | BE2016C051I2 (fr) |
BR (1) | BRPI0209249B8 (fr) |
CA (1) | CA2445344C (fr) |
DE (1) | DE60217674T2 (fr) |
DK (1) | DK1400518T3 (fr) |
ES (1) | ES2276931T3 (fr) |
FR (1) | FR16C0042I2 (fr) |
LU (1) | LU93266I2 (fr) |
MX (1) | MXPA03009800A (fr) |
NL (1) | NL300836I2 (fr) |
PT (1) | PT1400518E (fr) |
RU (1) | RU2283835C3 (fr) |
TW (1) | TWI316055B (fr) |
WO (1) | WO2002088084A1 (fr) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7326706B2 (en) | 2003-08-15 | 2008-02-05 | Bristol-Myers Squibb Company | Pyrazine modulators of cannabinoid receptors |
WO2005037199A2 (fr) | 2003-10-10 | 2005-04-28 | Bristol-Myers Squibb Company | Derives de pyrazole utilises comme modulateurs du recepteur de cannabinoide |
EP1763382A1 (fr) * | 2004-04-22 | 2007-03-21 | L'oreal | Compose 2-oxy-acetamide ses utilisations et compositions pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute |
FR2869224B1 (fr) * | 2004-04-22 | 2006-06-09 | Oreal | Compose 2-oxy-acetamide, ses utilisations et compositions pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute |
JP2008536950A (ja) * | 2005-04-18 | 2008-09-11 | ニューロジェン・コーポレーション | 置換ヘテロアリールのcb1拮抗薬 |
SI2246336T1 (sl) * | 2008-02-28 | 2020-09-30 | Nippon Shinyaku Co., Ltd. | Inhibitor fibroze |
CN103483226A (zh) * | 2008-03-18 | 2014-01-01 | 艾尼纳制药公司 | 用于治疗前列环素(pgi2)受体相关病症的pgi2受体调节剂 |
WO2009154246A1 (fr) * | 2008-06-19 | 2009-12-23 | 日本新薬株式会社 | Agent thérapeutique pour un dysfonctionnement érectile |
ES2611483T3 (es) * | 2008-06-23 | 2017-05-09 | Nippon Shinyaku Co., Ltd. | Agente terapéutico para enfermedad inflamatoria intestinal |
WO2009157397A1 (fr) * | 2008-06-23 | 2009-12-30 | 日本新薬株式会社 | Agent thérapeutique pour une lésion au tractus intestinal accompagnant l’administration d’un anti-inflammatoire nonstéroïdien |
EP2292231B1 (fr) * | 2008-06-23 | 2015-10-21 | Nippon Shinyaku Co., Ltd. | Agent thérapeutique pour la sténose du canal spinal |
CN102105453B (zh) | 2008-07-23 | 2016-05-25 | 东丽株式会社 | 慢性肾功能衰竭处置剂 |
JP5764061B2 (ja) * | 2008-08-13 | 2015-08-12 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | マシテンタン含有治療用組成物 |
PT3275871T (pt) * | 2009-06-26 | 2020-04-21 | Nippon Shinyaku Co Ltd | Cristais |
WO2011024874A1 (fr) * | 2009-08-26 | 2011-03-03 | 日本新薬株式会社 | Sels d'addition avec une base |
BR112012011237A2 (pt) | 2009-11-13 | 2019-09-24 | Univ Tokyo | agente terapêutico e profilático para diabetes |
US8809525B2 (en) | 2010-02-05 | 2014-08-19 | Heptares Therapeutics Limited | 1,2,4-triazine-4-amine derivatives |
SG186989A1 (en) * | 2010-07-14 | 2013-02-28 | Novartis Ag | Ip receptor agonist heterocyclic compounds |
AR089698A1 (es) | 2012-01-13 | 2014-09-10 | Novartis Ag | Compuestos heterociclicos antagonistas del receptor ip |
WO2013122029A1 (fr) | 2012-02-13 | 2013-08-22 | 武田薬品工業株式会社 | Composé à noyaux aromatiques |
JP6095580B2 (ja) | 2012-02-13 | 2017-03-15 | 武田薬品工業株式会社 | 芳香環化合物 |
EP2913047B1 (fr) | 2012-10-29 | 2019-05-08 | Cardio Incorporated | Agent thérapeutique spécifique de maladie pulmonaire |
US9604981B2 (en) | 2013-02-13 | 2017-03-28 | Novartis Ag | IP receptor agonist heterocyclic compounds |
JP6449166B2 (ja) | 2013-10-15 | 2019-01-09 | 小野薬品工業株式会社 | 薬剤溶出性ステントグラフト |
CN103588598B (zh) * | 2013-11-20 | 2015-06-17 | 苏州大学 | 一种制备2-烯醛衍生物的方法 |
CN104829465B (zh) | 2015-02-13 | 2018-04-27 | 普济生物科技(台州)有限公司 | 一种4-异丙氨基-1-丁醇的制备方法 |
CN106279047B (zh) | 2015-05-13 | 2019-05-03 | 普济生物科技(台州)有限公司 | 一种前列环素受体激动剂的制备方法 |
WO2016193994A1 (fr) | 2015-05-29 | 2016-12-08 | Megafine Pharma (P) Ltd. | Selexipag amorphe et son procédé de préparation |
CN106467496B (zh) * | 2015-08-14 | 2020-12-08 | 苏州国匡医药科技有限公司 | 4-[(5,6-二苯基哌嗪-2-基)(异丙基)胺基]-1-丁醇的制备方法 |
US10188648B2 (en) | 2015-09-03 | 2019-01-29 | Teva Pharmaceuticals International Gmbh | Solid state forms of selexipag |
WO2017042828A2 (fr) | 2015-09-10 | 2017-03-16 | Megafine Pharma (P) Ltd. | Procédé de préparation de sélexipag et intermédiaires de ce dernier |
WO2017042731A1 (fr) | 2015-09-10 | 2017-03-16 | Lupin Limited | Forme amorphe du sélexipag et dispersion solide associée |
WO2017060827A1 (fr) | 2015-10-07 | 2017-04-13 | Lupin Limited | Procédé amélioré pour la préparation de sélexipag ou de ses sels pharmaceutiquement acceptables |
UA124002C2 (uk) | 2015-12-02 | 2021-07-07 | Ніппон Сіняку Ко., Лтд. | Твердий препарат, що містить 2-{4-[n-(5,6- дифенілпіразин-2-іл)-n-ізопропіламіно]бутилокси}-n-(метилсульфоніл)ацетамід |
WO2017109772A1 (fr) * | 2015-12-20 | 2017-06-29 | Mapi Pharma Ltd. | Forme amorphe du sélexipag |
EP3204347A4 (fr) * | 2015-12-23 | 2018-03-28 | Commonwealth Scientific and Industrial Research Organisation | Composés |
EP3192502A1 (fr) | 2016-01-15 | 2017-07-19 | Sandoz Ag | Composition pharmaceutique de selexipag |
ES2911531T3 (es) * | 2016-04-01 | 2022-05-19 | Honour R&D | Procedimiento para la preparación de los derivados de difenilpirazina |
CN107286104A (zh) * | 2016-04-12 | 2017-10-24 | 常州方楠医药技术有限公司 | 一种赛乐西帕与药用辅料的固体分散体及其制备方法 |
CN105949135A (zh) * | 2016-05-10 | 2016-09-21 | 湖南欧亚生物有限公司 | 一种赛乐西帕的合成方法 |
US10544107B2 (en) * | 2016-07-05 | 2020-01-28 | Maithri Drugs Private Limited | Process for the preparation of 2-{4-[(5,6-diphenyl pyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide and novel polymorphs thereof |
WO2018015974A1 (fr) | 2016-07-20 | 2018-01-25 | Mylan Laboratories Limited | Formes polymorphes de sélexipag et dispersion solide amorphe de sélexipag |
WO2018015975A1 (fr) * | 2016-07-22 | 2018-01-25 | Sun Pharmaceutical Industries Limited | Dispersion solide amorphe de selxipag. |
WO2018022704A1 (fr) | 2016-07-26 | 2018-02-01 | Teva Pharmaceuticals International Gmbh | Forme cristalline vi de selexipag |
WO2018019296A1 (fr) * | 2016-07-29 | 2018-02-01 | 成都苑东生物制药股份有限公司 | Composé d'aminopyrazine, sel ou isomère, son procédé de préparation et son application |
WO2018021520A1 (fr) | 2016-07-29 | 2018-02-01 | 東レ株式会社 | Dérivé de guanidine et son utilisation à des fins médicales |
CN106316967B (zh) * | 2016-08-19 | 2019-02-05 | 上海艾康睿医药科技有限公司 | 西里帕格中间体及西里帕格的制备方法 |
WO2018078383A1 (fr) | 2016-10-27 | 2018-05-03 | Cipla Limited | Composition pharmaceutique comprenant du selexipag amorphe |
EP3554507A1 (fr) | 2016-12-14 | 2019-10-23 | Respira Therapeutics, Inc. | Procédés et compositions de traitement de l'hypertension pulmonaire et d'autres troubles des poumons |
KR102432505B1 (ko) | 2017-03-01 | 2022-08-12 | 아레나 파마슈티칼스, 인크. | Pgi2-수용체 효능제를 포함하는 조성물 및 그의 제조 방법 |
JOP20190204A1 (ar) | 2017-03-08 | 2019-09-05 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على سيليكسيباغ |
CN107365275B (zh) * | 2017-06-14 | 2020-07-03 | 杭州华东医药集团新药研究院有限公司 | 高纯度的赛乐西帕 |
RU2020106540A (ru) | 2017-07-27 | 2021-08-27 | Аллерган, Инк. | Агонисты простациклинового рецептора для уменьшения жировых отложений в организме |
SG11202002443QA (en) * | 2017-09-28 | 2020-04-29 | Nippon Shinyaku Co Ltd | Crystal |
US10407396B2 (en) * | 2017-11-16 | 2019-09-10 | Apotex Inc. | Crystalline form of selexipag |
BR112020008940A2 (pt) * | 2017-11-16 | 2020-10-20 | Nippon Shinyaku Co., Ltd. | preparação de liberação controlada |
EP3750879A1 (fr) * | 2018-02-07 | 2020-12-16 | Medshine Discovery Inc. | Agoniste du récepteur de la prostacycline |
AU2019225516A1 (en) | 2018-02-21 | 2020-10-08 | Nippon Shinyaku Co., Ltd. | Granular composition, production method for granular composition, and dissolution property improvement method for granular composition |
CN108558653A (zh) * | 2018-05-14 | 2018-09-21 | 湖南华腾制药有限公司 | 赛乐西帕中间体及赛乐西帕的制备方法 |
CN108863955B (zh) * | 2018-08-03 | 2021-08-13 | 成都苑东生物制药股份有限公司 | 二苯基吡嗪类化合物或其药学上可接受的盐、异构体及其制备方法和用途 |
CN108774183A (zh) * | 2018-08-03 | 2018-11-09 | 成都苑东生物制药股份有限公司 | 一种乙二醇类化合物的制备方法 |
CN109125325B (zh) * | 2018-09-25 | 2021-05-25 | 中国人民解放军总医院 | 前列环素受体激动剂的医药用途 |
WO2020225297A1 (fr) | 2019-05-06 | 2020-11-12 | Actelion Pharmaceuticals Ltd | Méthodes de traitement de l'hypertension pulmonaire associée à la sarcoïdose |
WO2020234361A2 (fr) | 2019-05-21 | 2020-11-26 | Actelion Pharmaceuticals Ltd | Méthodes de transition vers sélexipag |
JP2022536623A (ja) | 2019-06-11 | 2022-08-18 | アクテリオン ファーマシューティカルズ リミテッド | 肺動脈性肺高血圧症の治療方法 |
PE20220969A1 (es) * | 2019-08-19 | 2022-06-10 | Nippon Shinyaku Co Ltd | Sal |
JOP20220093A1 (ar) | 2019-10-23 | 2023-01-30 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على سيليكسيباغ |
TW202133851A (zh) | 2019-11-29 | 2021-09-16 | 瑞士商艾克泰聯製藥有限公司 | 治療肺動脈高血壓之方法 |
US11969424B2 (en) | 2019-12-16 | 2024-04-30 | Tenax Therapeutics, Inc. | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) |
JP2023512273A (ja) | 2020-01-31 | 2023-03-24 | アクテリオン ファーマシューティカルズ リミテッド | 制御放出セレキシパグ組成物 |
WO2021156227A1 (fr) | 2020-02-03 | 2021-08-12 | Actelion Pharmaceuticals Ltd | Méthodes de traitement et d'évaluation de l'hypertension artérielle pulmonaire au moyen de sélexipag |
WO2022106621A1 (fr) | 2020-11-20 | 2022-05-27 | Actelion Pharmaceuticals Ltd | Sélexipag destiné à être utilisé par l'intermédiaire d'une administration intracôlon |
TW202239408A (zh) | 2021-01-29 | 2022-10-16 | 瑞士商艾克泰聯製藥有限公司 | 包含二苯基吡𠯤衍生物的醫藥組成物 |
TW202241425A (zh) | 2021-01-29 | 2022-11-01 | 瑞士商艾克泰聯製藥有限公司 | 用於製造二苯基吡𠯤衍生物之程序 |
EP4316489A1 (fr) | 2021-03-31 | 2024-02-07 | Nippon Shinyaku Co., Ltd. | Agent thérapeutique contre un trouble de la marche |
JP7010404B1 (ja) | 2021-03-31 | 2022-02-10 | 日本新薬株式会社 | 歩行障害治療剤 |
WO2022238375A1 (fr) | 2021-05-11 | 2022-11-17 | Actelion Pharmaceuticals Ltd | Méthodes de traitement de l'hypertension pulmonaire |
CN113968824B (zh) * | 2021-11-29 | 2024-01-19 | 郑州大学 | 一种2,3,5-三取代吡嗪类化合物及其制备方法和应用 |
WO2023131608A1 (fr) | 2022-01-04 | 2023-07-13 | Actelion Pharmaceuticals Ltd | Compositions à libération contrôlée |
WO2023214059A1 (fr) | 2022-05-06 | 2023-11-09 | Actelion Pharmaceuticals Ltd | Composés de diphénylpyrazine utilisés en tant que promédicaments |
WO2024017964A1 (fr) | 2022-07-20 | 2024-01-25 | Actelion Pharmaceuticals Ltd | Composition pharmaceutique injectable comprenant un dérivé de diphénylpyrazine |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH633541A5 (en) | 1977-05-17 | 1982-12-15 | Diamond Shamrock Corp | Pharmacologically active substituted 1,2,4-triazines and medicaments containing these triazines |
US4513135A (en) * | 1982-03-05 | 1985-04-23 | Eli Lilly And Company | Diaryl-pyrazine derivatives affecting GABA binding |
FR2665159B1 (fr) * | 1990-07-24 | 1992-11-13 | Rhone Poulenc Sante | Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent. |
WO1992002513A1 (fr) | 1990-08-06 | 1992-02-20 | Fujisawa Pharmaceutical Co., Ltd. | Composes heterocycliques |
US5219510A (en) * | 1990-09-26 | 1993-06-15 | Eastman Kodak Company | Method of manufacture of cellulose ester film |
JP3169413B2 (ja) * | 1992-01-31 | 2001-05-28 | エーザイ株式会社 | イミダゾール誘導体 |
JPH0733752A (ja) * | 1993-07-16 | 1995-02-03 | Sankyo Co Ltd | ジフェニルピラジン誘導体及び除草剤 |
AUPP003297A0 (en) * | 1997-10-27 | 1997-11-20 | Fujisawa Pharmaceutical Co., Ltd. | 4,5-diaryloxazole compounds |
AUPQ253199A0 (en) * | 1999-08-30 | 1999-09-23 | Fujisawa Pharmaceutical Co., Ltd. | Non-prostanoid prostaglandin I2-agonist |
-
2002
- 2002-04-24 TW TW091108440A patent/TWI316055B/zh active
- 2002-04-25 BR BRPI0209249A patent/BRPI0209249B8/pt active IP Right Grant
- 2002-04-25 CA CA2445344A patent/CA2445344C/fr not_active Expired - Lifetime
- 2002-04-25 US US10/476,196 patent/US7205302B2/en active Active
- 2002-04-25 PT PT02722772T patent/PT1400518E/pt unknown
- 2002-04-25 EP EP02722772A patent/EP1400518B1/fr not_active Expired - Lifetime
- 2002-04-25 DK DK02722772T patent/DK1400518T3/da active
- 2002-04-25 WO PCT/JP2002/004118 patent/WO2002088084A1/fr active IP Right Grant
- 2002-04-25 DE DE60217674T patent/DE60217674T2/de not_active Expired - Lifetime
- 2002-04-25 RU RU2003134190A patent/RU2283835C3/ru active Protection Beyond IP Right Term
- 2002-04-25 KR KR1020037014044A patent/KR100921760B1/ko active Protection Beyond IP Right Term
- 2002-04-25 CN CNB028089774A patent/CN1301973C/zh not_active Expired - Lifetime
- 2002-04-25 ES ES02722772T patent/ES2276931T3/es not_active Expired - Lifetime
- 2002-04-25 MX MXPA03009800A patent/MXPA03009800A/es active IP Right Grant
- 2002-04-25 JP JP2002585386A patent/JP4479152B2/ja not_active Expired - Lifetime
-
2016
- 2016-10-18 NL NL300836C patent/NL300836I2/nl unknown
- 2016-10-19 LU LU93266C patent/LU93266I2/fr unknown
- 2016-10-24 FR FR16C0042C patent/FR16C0042I2/fr active Active
- 2016-11-03 BE BE2016C051C patent/BE2016C051I2/fr unknown
Also Published As
Publication number | Publication date |
---|---|
EP1400518A4 (fr) | 2005-04-20 |
DK1400518T3 (da) | 2007-03-26 |
TWI316055B (fr) | 2009-10-21 |
BE2016C051I2 (fr) | 2021-07-19 |
ES2276931T3 (es) | 2007-07-01 |
CA2445344C (fr) | 2011-07-26 |
EP1400518B1 (fr) | 2007-01-17 |
RU2283835C3 (ru) | 2021-02-15 |
MXPA03009800A (es) | 2004-01-29 |
EP1400518A1 (fr) | 2004-03-24 |
FR16C0042I1 (fr) | 2016-12-09 |
WO2002088084A1 (fr) | 2002-11-07 |
PT1400518E (pt) | 2007-03-30 |
KR20040015174A (ko) | 2004-02-18 |
CA2445344A1 (fr) | 2002-11-07 |
JPWO2002088084A1 (ja) | 2004-09-09 |
BR0209249A (pt) | 2004-06-08 |
LU93266I2 (fr) | 2016-12-19 |
DE60217674D1 (de) | 2007-03-08 |
BRPI0209249B8 (pt) | 2021-05-25 |
DE60217674T2 (de) | 2007-10-11 |
CN1301973C (zh) | 2007-02-28 |
BRPI0209249B1 (pt) | 2016-04-26 |
RU2003134190A (ru) | 2005-06-10 |
RU2283835C2 (ru) | 2006-09-20 |
CN1516690A (zh) | 2004-07-28 |
NL300836I2 (fr) | 2016-11-16 |
KR100921760B1 (ko) | 2009-10-15 |
US7205302B2 (en) | 2007-04-17 |
US20040102436A1 (en) | 2004-05-27 |
JP4479152B2 (ja) | 2010-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR16C0042I2 (fr) | Derives de composes heterocycliques et medicaments | |
EE200200357A (et) | Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid | |
PT1221918E (pt) | Administracao de drogas sub-tenon | |
EE05123B1 (et) | Antiprogestiinsete omadustega ravimite manustamise vahendid | |
FR2847253B1 (fr) | Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant | |
IL160714A0 (en) | Heterocyclic substituted 2-(4-phenoxy) pyridine derivatives and pharmaceutical compositions containing the same | |
AU2002331391A1 (en) | N-monoacylated derivatives of o-phenylenediamines, their six membered heterocyclic analogues and their use as pharmaceutical agents | |
LTC1345910I2 (lt) | Chinazolidino dariniai, minėtus junginius turintys vaistai, jų panaudojimas ir jų gavimo būdas | |
NO20042842L (no) | Farmasoytiske formuleringer av platina-derivat | |
EE04418B1 (et) | Moksifloksatsiini farmatseutiline preparaat | |
NO20000225D0 (no) | Retarderte legemiddelformuleringer inneholdende en kombinasjon av et opioid og en -agonist | |
NO20013945D0 (no) | Fremstilling av isoflavonderivater | |
DE60201859D1 (de) | Pharmazeutische Verwendung von N-Carbamoylazol-Derivate | |
BRPI0209720A2 (pt) | dosagem e embalagem de medicação com liberação controlada | |
IL157740A0 (en) | Heterocyclic derivatives and pharmaceutical compositions containing the same | |
NO20022021D0 (no) | Indeno-, nafto- og benzocyklohepta-dihydrotiazolderivater, fremstilling av de samme og deres anvendelse somanoreksilegemidler | |
IL161854A0 (en) | Heterocyclic derivatives of glycinamide and their medical use | |
PL367676A1 (en) | Novel heterocyclic derivatives and medicinal use thereof | |
IL159085A0 (en) | Heterocyclic derivatives and pharmaceutical compositions containing the same | |
ATE362915T1 (de) | Heterocyclische derivate und arzneistoffe | |
DE60139306D1 (de) | N-deacetylthiocolchin-derivate und diese enthaltende arzneimittel | |
PT1178984E (pt) | Derivados de 1-trifluorometil-4-hidroxi-7-piperidinilamimometilcromano | |
HUP0204560A3 (en) | Heterocyclic amide derivatives and pharmaceutical compositions containing them and their use | |
EE200300454A (et) | Bitsüklilised guanidiini derivaadid ja nende terapeutiline kasutamine | |
DE60214533D1 (de) | Pyridoindolonderivate und antikrebsmittel enthaltende pharmazeutische mischungen |